Data from: Blockade of dengue virus transmission from viremic blood to Aedes aegypti mosquitoes using human monoclonal antibodies

Background Dengue is the most prevalent arboviral disease of humans. Virus
neutralizing antibodies are likely to be critical for clinical immunity
after vaccination or natural infection. A number of human monoclonal
antibodies (mAbs) have previously been characterized as able to neutralize
the infectivity of dengue virus (DENV) for mammalian cells in cell-culture
systems.   Methodology/Principle findings We tested the capacity
of 12 human mAbs, each of which had previously been shown to neutralize
DENV in cell-culture systems, to abrogate the infectiousness of dengue
patient viremic blood for mosquitoes. Seven of the twelve mAbs (1F4,
14c10, 2D22, 1L12, 5J7, 747(4)B7, 753(3)C10), almost all of which target
quaternary epitopes, inhibited DENV infection of Ae. aegypti. The mAbs
14c10, 747(4)B7 and 753(3)C10 could all inhibit transmission of DENV in
low microgram per mL concentrations. An Fc-disabled variant of 14c10 was
as potent as its parent mAb.   Conclusions/Significance The
results demonstrate that mAbs can neutralize infectious DENV derived from
infected human cells, in the matrix of human blood. Coupled with previous
evidence of their ability to prevent DENV infection of mammalian cells,
such mAbs could be considered attractive antibody classes to elicit with
dengue vaccines, or alternatively, for consideration as therapeutic
candidates.